|1.||Stephan, Bernd: 5 articles (02/2013 - 06/2007)|
|2.||Silley, Peter: 3 articles (05/2012 - 11/2007)|
|3.||Greife, Heinrich A: 3 articles (05/2012 - 11/2007)|
|4.||Pridmore, Andrew: 3 articles (05/2012 - 11/2007)|
|5.||Wetzstein, H-G: 2 articles (12/2012 - 10/2005)|
|6.||Lappin, Michael R: 2 articles (01/2009 - 10/2008)|
|7.||Radecki, Steven V: 2 articles (01/2009 - 10/2008)|
|8.||Hartmann, K: 2 articles (04/2008 - 01/2008)|
|9.||Blondeau, Joseph M: 1 article (08/2014)|
|10.||Sykes, Jane E: 1 article (08/2014)|
06/01/2007 - "Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial."
12/01/2012 - "Pradofloxacin (PRA), a novel veterinary 8-cyano-fluoroquinolone (FQ), is active against Staphylococcus pseudintermedius, the primary cause of canine pyoderma. "
06/01/2007 - "A multicentre, randomized, blinded study compared the efficacy of pradofloxacin with that of a combination of amoxycillin/clavulanic acid in the treatment of deep pyoderma in dogs. "
09/01/2010 - "Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma."
06/01/2007 - "These results indicate that pradofloxacin is an efficacious therapy comparable to amoxycillin/clavulanic acid for deep bacterial pyoderma in dogs."
02/22/2013 - "In this study, 908 bacterial pathogens from defined infections of dogs and cats were tested for their susceptibility to the novel fluoroquinolone pradofloxacin, which was approved in 2011 for use in cats and dogs. "
06/01/2013 - "Pradofloxacin is a third-generation fluoroquinolone, licensed in the EU for use in a range of indications in the dog and cat and authorized more recently in the USA for one therapeutic indication (skin infections) in the cat. "
01/01/2013 - "Despite some technical shortcomings the ultrafiltration approach appears to be the most sensitive sampling technique to estimate pharmacokinetic values of pradofloxacin at the infection site. "
01/01/2009 - "Use of pradofloxacin to treat experimentally induced Mycoplasma hemofelis infection in cats."
11/01/2007 - "Pradofloxacin, a novel third-generation fluoroquinolone, has broad-spectrum anti-anaerobe activity and offers utility as single-drug therapy for mixed aerobic/anaerobic infections."
|3.||Urinary Tract Infections (Urinary Tract Infection)
09/01/2007 - "We conclude that pradofloxacin 2.5% oral suspension is a highly effective and safe antimicrobial treatment for bacterial lower urinary tract infection in cats, and that the palatable formulation optimizes owner compliance. "
02/01/2013 - "Because in vitro efficacy was greatest for pradofloxacin; it might be preferred for treatment of urinary tract infections (UTIs) associated with FQ susceptible E. "
09/01/2007 - "Pradofloxacin 2.5% oral suspension is a safe, efficacious, and palatable treatment for bacterial urinary tract infections (UTI) in cats. "
09/01/2007 - "Clinical efficacy and palatability of pradofloxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infections in cats."
|4.||Respiratory Tract Diseases (Respiratory Tract Disease)
|1.||Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)
|6.||DNA (Deoxyribonucleic Acid)
|2.||Drug Therapy (Chemotherapy)